The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksForterra Regulatory News (FORT)

Share Price Information for Forterra (FORT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 162.60
Bid: 161.00
Ask: 161.40
Change: 2.60 (1.63%)
Spread: 0.40 (0.248%)
Open: 160.00
High: 163.60
Low: 160.00
Prev. Close: 160.00
FORT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

11 Oct 2023 07:00

RNS Number : 6927P
Forterra plc
11 October 2023

11 October 2023

FORTERRA PLC

Q3 Trading Update

Forterra plc (the 'Group'), a leading UK manufacturer of essential clay and concrete building products, provides this third quarter trading update for the nine-month period ending 30 September 2023 (the 'period').

Key points

· The signs of market improvement seen in May and June did not continue into the second half with market demand deteriorating in July and August.

· Figures published by the Department of Business and Trade show UK brick despatches in July and August 2023 averaged 16% lower than in June 2023, and 28% lower than in the corresponding period in 2022. Within this, August was weaker than July and our own despatches suggest a further softening in September. These figures also highlight that UK brick industry despatches are currently running below the levels seen in 2009.

· Despite the weak demand, pricing across our range of products has remained resilient overall.

· In July we guided to a full year 2023 EBITDA with a more balanced H1/H2 split, based on the assumption that the levels of demand seen in June would continue. However, we are now anticipating demand to remain at the levels which we have experienced over the past quarter and accordingly expect full year EBITDA to be below previous expectations.

· Following previously announced management actions, we have taken further steps to align our production levels with market demand. Consultation is currently underway on the mothballing of a further brick factory at Claughton in Lancashire along with cuts to production in our Aircrete business. The market weakness seen in recent months, coupled with the lead time associated with efficiently reducing production, will lead to our inventory build in 2023 being higher than previously anticipated.

· Commissioning of the new Desford brick factory continues to progress, with the challenges of replicating the product range now overcome. Although output in the last quarter was below plan, the weaker market demand has meant there was no impact on sales.

· Looking ahead we expect to manage our operations on the assumption that 2024 demand will be at a similar level to 2023 and, accordingly we will look to align production output with this level of sales, thereby limiting further inventory growth.

· As we set out at the half year, we expect FY24 results to benefit from a more stable energy cost environment, a stabilisation of customer inventory, the substitution of imported bricks as well as the full year benefit of previously announced cost reductions, offset by reduced operating efficiency driven by a reduction in production.

· Growing political focus on increasing housing supply ahead of a general election reinforces the Board's confidence in the long-term industry fundamentals and the Board remains confident that the Group remains well placed to benefit when market demand recovers.

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) No 596/2014.

ENQUIRIES

Forterra plc +44 1604 707 600

Neil Ash, Chief Executive Officer

Ben Guyatt, Chief Financial Officer

FTI Consulting +44 203 727 1340

Richard Mountain / Nick Hasell

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTEAKEEFLLDFFA
Date   Source Headline
15th Apr 20241:46 pmRNSAnnual Report & Accounts 2023 & Notice of AGM 2024
12th Apr 202412:09 pmRNSDirector/PDMR Shareholding
9th Apr 20244:22 pmRNSDirector/PDMR Shareholding
9th Apr 20244:19 pmRNSDirector/PDMR Shareholding
3rd Apr 20242:19 pmRNSDirector/PDMR Shareholding
27th Mar 20244:44 pmRNSDirector/PDMR Shareholding
25th Jan 202412:27 pmRNSDirector Declaration
24th Jan 20247:19 amRNSProgressive publish new research
24th Jan 20247:00 amRNS2023 Trading Update
23rd Jan 20247:00 amRNSHolding(s) in Company
8th Dec 20237:00 amRNSDirector Declaration
9th Nov 20237:00 amRNSAppointment of Joint Corporate Broker
20th Oct 20236:05 pmRNSDirector/PDMR Shareholding
11th Oct 20237:00 amRNSQ3 Trading Update
5th Oct 20235:04 pmRNSGrant of Options under 2023 SAYE Scheme
11th Sep 20237:00 amRNSHolding(s) in Company
1st Sep 20235:46 pmRNSHolding(s) in Company
23rd Aug 20233:59 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSSix months ended 30 June 2023
11th Jul 20237:00 amRNSPost close half year trading update
5th Jul 202312:39 pmRNSEmployee Benefit Trust Share Purchase
30th Jun 20231:51 pmRNSHolding(s) in Company
6th Jun 202312:57 pmRNSEmployee Benefit Trust Share Purchase
23rd May 20232:22 pmRNSAnnual General Meeting 2023 Results
18th May 202312:12 pmRNSProgressive publish new research
16th May 20237:00 amRNSPre-AGM trading update
5th May 20234:39 pmRNSDirector/PDMR Shareholding
4th May 20239:00 amRNSEmployee Benefit Trust Share Purchase
25th Apr 20237:00 amRNSNotification of Board Changes
11th Apr 20234:15 pmRNSPCA Shareholdings
4th Apr 20231:12 pmRNSEmployee Benefit Trust Share Purchase
3rd Apr 20232:03 pmRNSGrant under Performance Share Plan
29th Mar 202310:21 amRNSAnnual Report & Accounts 2022 & Notice of AGM 2023
16th Mar 20235:28 pmRNSGrant under Deferred Annual Bonus Plan
10th Mar 20239:18 amRNSProgressive publishes new research
9th Mar 20237:02 amRNSAppointment of Independent Non-Executive Director
9th Mar 20237:00 amRNSFull Year Results
3rd Mar 20232:18 pmRNSEmployee Benefit Trust Share Purchase
3rd Feb 202310:13 amRNSEmployee Benefit Trust Share Purchase
1st Feb 20238:18 amRNSDirector Declaration
25th Jan 20237:00 amRNSTrading Update
5th Jan 20233:12 pmRNSEmployee Benefit Trust Share Purchase
14th Dec 20225:10 pmRNSEmployee Benefit Trust Share Purchase
8th Dec 20227:00 amRNSHolding(s) in Company
2nd Dec 20224:10 pmRNSEmployee Benefit Trust Share Purchase
22nd Nov 20227:54 amRNSProgressive publishes new research
22nd Nov 20227:01 amRNSAppointment of Chief Executive Officer
22nd Nov 20227:00 amRNSTrading Update
4th Nov 20222:50 pmRNSEmployee Benefit Trust Share Purchase
2nd Nov 20228:45 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.